Clinical Trial Update: A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing LCZ696 (sacubitril/valsartan) to standard medical therapy in patients with heart failure with preserved ejection fraction (HF…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 3 | Status: COMPLETED | Results posted: 2021-02-08